Floatz logo

128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified

Therapeutic assets addressing Peripheral T-Cell Lymphoma, Not Otherwise Specified, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ivarmacitinib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Fudan UniversityP2CCC (55)
Lacutamab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Innate PharmaP2CCC (55)
Ruxolitinib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Jonathan BrammerP2CCC (55)
Duvelisib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
City of Hope Medical CenterP2CCC (54)
Aclarubicin
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Shanghai Jiao Tong University School of MedicineP2CCC (53)
Endoxan
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Czech Lymphoma Study GroupP2CCC (53)
Fenretinide
Peripheral T-Cell Lymphoma, Not Otherwise Specified
SciTech Development, Inc.P2CCC (53)
Ifupinostat Hydrochloride For
Peripheral T-Cell Lymphoma, Not Otherwise Specified
BeBetter Med IncP2CCC (53)
Purinostat
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Chengdu Zenitar Biomedical Technology Co., LtdP2CCC (53)
Shr-2554
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Fudan UniversityP2CCC (53)
Toripalimab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2CCC (53)
Valemetostat
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Daiichi SankyoP2CCC (53)
Cidabenamine
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineP2/3CCC (52)
Cmoep
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
M-Sympathol
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Affimed GmbHP2CCC (51)
Thiotepa
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Xianmin Song, MDP2CCC (51)
Parsaclisib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Fudan UniversityP1/2CCC (49)
Adebrelimab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Sun Yat-sen UniversityP1/2CCC (48)
azd3470
Peripheral T-Cell Lymphoma, Not Otherwise Specified
AstraZenecaP1/2CCC (48)
Durvalumab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
City of Hope Medical CenterP1/2CCC (48)
gfh009
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Genfleet Therapeutics (Shanghai) Inc.P1/2CCC (48)
Golcadomide
Peripheral T-Cell Lymphoma, Not Otherwise Specified
The Lymphoma Academic Research OrganisationP1/2CCC (48)
Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Dren BioP1/2CCC (48)
Immunoglobulin G4 [221-Proline], Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Sg001 ?4-Chain), Disulfide With Human Monoclonal Sg001 ?-Chain, Dimer
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Sun Yat-Sen University Cancer CenterP1/2CCC (48)
lis1
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Xenothera SASP1/2CCC (48)
mt-101
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Myeloid TherapeuticsP1/2CCC (48)
Roginolisib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
The Lymphoma Academic Research OrganisationP1/2CCC (48)
Immunoglobulin G1, Anti-(Human Programmed Death-Ligand 1) (Human Monoclonal Sti-3031 .Gamma.1-Chain), Disulfide With Human Monoclonal Sti-3031 .Lambda.-Chain, Dimer
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Sorrento Therapeutics, Inc.P2CC (47)
kt-333
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Kymera Therapeutics, Inc.P1CC (47)
zx-101a
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Nanjing Zenshine PharmaceuticalsP1/2CC (46)
cd5-targeted car-t cells
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Peking University People's HospitalP1/2CC (45)
Abatacept Recombinant
Peripheral T-Cell Lymphoma, Not Otherwise Specified
National Cancer Institute (NCI)P1CC (43)
Autologous Bcma/Cd19 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Bcma/Cd38 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Bcma/Gprc5D Dual-Target Car-T
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Cd19/Cd20 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Cd19/Cd22 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Cd33/Cd123 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Cd33/Cll1 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
Autologous Cd5/Cd7 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing BiotechP1/2CC (43)
BP1002
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Bio-Path Holdings, Inc.P1CC (43)
br1733
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Shanghai Blueray Biopharma Co., Ltd.P1/2CC (43)
Cedazuridine
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Taiho Oncology, Inc.P1CC (43)
Daratumumab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CellCentric Ltd.P1/2CC (43)
Dasatinib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Ruijin HospitalP1/2CC (43)
Elranatamab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CellCentric Ltd.P1/2CC (43)
Epsametostat
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Haihe Biopharma Co., Ltd.P1/2CC (43)
Fludeoxyglucose
Peripheral T-Cell Lymphoma, Not Otherwise Specified
City of Hope Medical CenterP1CC (43)
Inobrodib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CellCentric Ltd.P1/2CC (43)
lb1901
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Legend Biotech USA IncP1CC (43)
Showing 51 to 100 of 128 assets
PreviousPage 2 of 3Next